Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
Morgan D. McSweeney, Ian E. Stewart, Zach Richardson, et al.
Bioengineering & Translational Medicine (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 14

Showing 14 citing articles:

Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 197
Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections
Morgan D. McSweeney, Sarhad Alnajjar, Alison Schaefer, et al.
Advanced Science (2024) Vol. 11, Iss. 12
Open Access | Times Cited: 7
An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models
Emiko Urano, Yumi Itoh, Tatsuya Suzuki, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 711
Closed Access | Times Cited: 14
Engineering a “muco‐trapping” ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19
Karthik Tiruthani, Carlos Cruz‐Teran, Jasper Fuk‐Woo Chan, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 3
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
Juan Liu, Fengfeng Mao, Jianhe Chen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Antibody protection from SARS-CoV-2 respiratory tract exposure and infection
Alex Chen, Timothy Wessler, M. Gregory Forest
Journal of Theoretical Biology (2022) Vol. 557, pp. 111334-111334
Open Access | Times Cited: 9
Long-acting inhaled medicines: Present and future
Chengqian Zhang, Davide D’Angelo, Francesca Buttini, et al.
Advanced Drug Delivery Reviews (2023) Vol. 204, pp. 115146-115146
Open Access | Times Cited: 4
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Wenli Sun, Yanling Wu, Tianlei Ying
Antiviral Research (2024) Vol. 225, pp. 105867-105867
Open Access
ZMapp reduces diffusion of Ebola viral particles in fresh human cervicovaginal mucus
Alison Schaefer, Bing Yang, Holly A. Schroeder, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access
Dry powder formulations of hyperimmune serum
Annalisa Bianchera, Gaetano Donofrío, Fabio Sonvico, et al.
Drug Delivery and Translational Research (2024)
Open Access
Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium
Kohei Togami, Whitney Wolf, Lucas C. Olson, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview
Noémie Alphonse, Thomas Sécher, Nathalie Heuzé-Vourc’h
Expert Opinion on Drug Delivery (2024)
Closed Access
Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases
Thomas Sécher, Nathalie Heuzé-Vourc’h
AAPS introductions in the pharmaceutical sciences (2023), pp. 21-51
Closed Access | Times Cited: 1
Page 1

Scroll to top